Capture

PRODUCTS

  • Manipulator machines can process a wide range of different containers such as vials, cartridges, and prefilled syringes, either bulk or nested, in order to meet the current pharmaceutical industry requirements and to address the end users' needs. They are designed to ensure the integrity of high-value products such as biotechnology, nuclear, cytotoxic, and more, or to treat different containers with a single machine thanks to the use of manipulator robots. These machines can be customized by joining our professional skills in filling and inspection applications and users' requirements.

  • Polyzen is an innovative leader in the manufacturing and processing of components for a wide range of medical devices and is a preferred supplier to medical device OEMs worldwide. Extensive in-house processing capabilities and process technology experts enable us to manufacture an array of plastic components. These include medical grade polymer films and laminates, lay-flat tubing, balloons, bags, sleeves, stent and catheter coatings, and much more.

  • Unleash the potential in your cell therapy with scalable, single-use bioreactors from 0.1L to 80L, empowering scientists to develop cell therapy products that combat cancer, diabetes, and heart failure. 

  • Many biotechnology companies come to Australia to conduct early phase clinical trials and take advantage of straightforward regulatory streams and of the lucrative 43.5% R&D cash refund scheme. Biotechnology companies then often look at locations in Asia, such as South Korea, Thailand and China to tap into their huge treatment-naïve patient populations for their later phase clinical research.

  • Our comprehensive package of both autologous and allogeneic cell therapy manufacturing services includes GMP production of cells from pre-clinical to commercial applications from a variety of starting materials. As an experienced cell therapy CDMO, we’re able to swiftly scale-up and support production from clinical to commercial manufacturing. Need help with the development of your cell therapy?

WHITE PAPERS AND CASE STUDIES

NEWS